Cancer is the most serious disease in the history of
mankind. All families in the U.S. and the world are affected by cancer either
directly or indirectly. Men, women, and children of all races, creeds, and
religions risk the possibility of being diagnosed with cancer – it does not
discriminate. Some startling estimates for 2016 from the American Cancer
Society are as follows: 841,390 new cancer cases in males in the U.S.; 843,820
new cancer cases in females in the U.S.; 314,290 deaths from cancer in males in
the U.S.; and 281,400 deaths from cancer in females in the U.S.
Immune Therapeutics, Inc. (OTCQB: IMUN) is a biotechnology
company applying its patented immunotherapy to combat chronic, life-threatening
diseases that affect people around the world. Building on the power of the
body’s natural immune system, the company’s pipeline of products and immunotherapy
technologies are designed to enhance the treatment of cancer, infections such
as HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune
diseases.
Each year, cancer costs the world more money than any other
disease, according to the American Institute of Cancer Research (AICR). Cancer
costs $895 billion annually. Comparatively, heart disease costs $753 billion.
Nothing else comes close, with traffic accidents and diabetes each costing
about $204 billion. The biggest financial impact is in terms of loss of life
and productivity, in which cancer accounts for 1.5 percent of global gross
domestic product (GDP) losses.
Immunotherapy, also called biologic therapy, is a type of
cancer treatment designed to boost the body’s natural defenses to fight the
cancer. It uses materials either made by the body or in a laboratory to
improve, target, or restore immune system function.
Stimulating the body’s immune system remains one of the most
promising approaches to addressing the unmet needs of cancers, HIV,
inflammatory disease, autoimmune disease and other chronic infectious diseases.
Immune Therapeutics’ immune therapy technology platform has shown the potential
to establish a new paradigm to prevent and treat these life-altering diseases,
with validating efficacy data from all phase I and phase II clinical trials for
such diseases as HIV/AIDS, pancreatic cancer, Crohn’s Disease, liver disease,
fibromyalgia and herpes.
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment